Ursomax Special Precautions

ursodeoxycholic acid


Mega Lifesciences


Full Prescribing Info
Special Precautions
Liver tests: Patients given ursodeoxycholic acid should have SGPT (ALT), SGOT(AST), GGT, ALP and bilirubin measured at the initiation of therapy and thereafter as indicated by the particular clinical circumstances. Monitoring of serum values is recommended upon initiation of treatment, every 1 to 3 months for the first 3 months of treatment (depending on the indication for use), and then every 6 months during treatment; ursodeoxycholic acid must be discontinued if increased values persist.
Use in Pregnancy & Lactation: Should not be used during pregnancy and lactation without medical advice.
Use in Children: Safety and efficacy have not been established.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in